Lowest-Rated StocksLowest-RatedNYSE:TEVA Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price & News $7.38 +0.15 (+2.07%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$7.24▼$7.4350-Day Range$7.19▼$9.4752-Week Range$6.78▼$11.44Volume21.98 million shsAverage Volume18.87 million shsMarket Capitalization$8.27 billionP/E RatioN/ADividend YieldN/APrice Target$10.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Teva Pharmaceutical Industries MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside44.5% Upside$10.67 Price TargetShort InterestHealthy1.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth6.39%From $2.19 to $2.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector438th out of 981 stocksPharmaceutical Preparations Industry195th out of 467 stocks 3.0 Analyst's Opinion Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 4 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.67, Teva Pharmaceutical Industries has a forecasted upside of 44.5% from its current price of $7.38.Amount of Analyst CoverageTeva Pharmaceutical Industries has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.25% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently increased by 9.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TEVA. Previous Next 3.3 News and Social Media Coverage News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Teva Pharmaceutical Industries this week, compared to 6 articles on an average week.Search InterestOnly 35 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows7 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.82% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions50.39% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 6.39% in the coming year, from $2.19 to $2.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 1.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Teva Pharmaceutical Industries (NYSE:TEVA) StockTeva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.Read More Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TEVA Stock News HeadlinesJune 6, 2023 | markets.businessinsider.comPhil, Teva Partner To Help Patients To Receive, Refill Digihaler MedicationJune 6, 2023 | finance.yahoo.comPhil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma ManagementJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. June 5, 2023 | finance.yahoo.comTeva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?June 2, 2023 | benzinga.comGlobal Small Molecule Active Pharmaceutical Ingredient Market Report 2023: Increasing Prevalence of Diseases is a Major DriverJune 2, 2023 | finance.yahoo.comTeva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023May 29, 2023 | finance.yahoo.comShareholders in Teva Pharmaceutical Industries (NYSE:TEVA) have lost 66%, as stock drops 6.3% this past weekMay 27, 2023 | americanbankingnews.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $10.86 Consensus Target Price from AnalystsJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 26, 2023 | seekingalpha.comTeva considering potential sale of inflammatory bowel disease asset - BloombergMay 25, 2023 | msn.comTeva Explores Options for Bowel Inflammation DrugMay 25, 2023 | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) Research Coverage Started at Morgan StanleyMay 18, 2023 | markets.businessinsider.comTeva Pharma Announces New Strategic Framework; Reiterates 2027 Financial TargetsMay 18, 2023 | reuters.comTeva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027May 18, 2023 | finance.yahoo.comTeva to Slim Down Generic Drug Business in Turnaround Effort. The Stock Is Jumping.May 18, 2023 | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) Now Covered by StockNews.comMay 17, 2023 | marketwatch.comIgA Nephropathy Disease Treatment Market Size, Share, Industry Growing Rapidly with Recent Trends, Development, Revenue by 2030May 16, 2023 | msn.comAstraZeneca to exit leading U.S. drug industry group PhRMAMay 15, 2023 | msn.comUS Supreme Court rejects Teva challenge to $235 million GSK award in patent disputeMay 15, 2023 | finance.yahoo.comAUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.May 15, 2023 | finance.yahoo.comUPDATE 1-US Supreme Court rejects Teva challenge to $235 million GSK award in patent disputeMay 12, 2023 | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down to $9.10May 11, 2023 | marketwatch.com8-K: TEVA PHARMACEUTICAL INDUSTRIES LTDMay 11, 2023 | msn.comUPDATE 2-Teva Pharm Q1 net profit slides, maintains 2023 forecastMay 11, 2023 | marketwatch.com2023, Cancer Cachexia Therapeutics Market | Global Industry Analysis Till 2030May 11, 2023 | finance.yahoo.comTEVA Q1 Earnings Miss Estimates, Sales Beat, Stock DeclinesMay 11, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)See More Headlines TEVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TEVA Company Calendar Last Earnings5/10/2023Today6/08/2023Next Earnings (Estimated)7/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TEVA CUSIPN/A CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees36,826Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.67 High Stock Price Forecast$14.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+44.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E Ratio3.37 P/E Growth1.29Net Income$-2,353,000,000.00 Net Margins-10.73% Pretax Margin-15.76% Return on Equity27.58% Return on Assets5.69% Debt Debt-to-Equity Ratio2.28 Current Ratio1.10 Quick Ratio0.71 Sales & Book Value Annual Sales$14.93 billion Price / Sales0.55 Cash Flow$3.69 per share Price / Cash Flow2.00 Book Value$7.82 per share Price / Book0.94Miscellaneous Outstanding Shares1,120,410,000Free Float1,111,219,000Market Cap$8.27 billion OptionableOptionable Beta1.18 Key ExecutivesRichard FrancisPresident, Chief Executive Officer & DirectorEric DrapéExecutive Vice President-Global OperationsEli KalifChief Financial Officer & Executive Vice PresidentEric A. HughesChief Medical Officer, Executive VP-Global R&DKathleen VeitSenior VP-Global Compliance & Ethics OfficerKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZRoivant SciencesNASDAQ:ROIVKaruna TherapeuticsNASDAQ:KRTXCatalentNYSE:CTLTDr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 2,157 shares on 5/22/2023Ownership: 0.011%Advanced Portfolio Management LLCBought 300,000 shares on 5/19/2023Ownership: 0.027%Centaurus Financial Inc.Sold 2,195 shares on 5/18/2023Ownership: 0.001%New York State Common Retirement FundSold 1,748 shares on 5/18/2023Ownership: 0.001%AIMZ Investment Advisors LLCSold 1,500 shares on 5/16/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions TEVA Stock - Frequently Asked Questions Should I buy or sell Teva Pharmaceutical Industries stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares. View TEVA analyst ratings or view top-rated stocks. What is Teva Pharmaceutical Industries' stock price forecast for 2023? 10 Wall Street analysts have issued 1 year target prices for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 44.5% from the stock's current price. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts. How have TEVA shares performed in 2023? Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of 2023. Since then, TEVA shares have decreased by 19.1% and is now trading at $7.38. View the best growth stocks for 2023 here. Are investors shorting Teva Pharmaceutical Industries? Teva Pharmaceutical Industries saw a decline in short interest in April. As of April 30th, there was short interest totaling 12,730,000 shares, a decline of 16.6% from the April 15th total of 15,260,000 shares. Based on an average trading volume of 8,860,000 shares, the short-interest ratio is presently 1.4 days. View Teva Pharmaceutical Industries' Short Interest. When is Teva Pharmaceutical Industries' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023. View our TEVA earnings forecast. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its quarterly earnings data on Wednesday, May, 10th. The company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.55 by $0.18. The company earned $3.66 billion during the quarter, compared to analyst estimates of $3.60 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 27.58% and a negative net margin of 10.73%. What ETFs hold Teva Pharmaceutical Industries' stock? ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Israel ETF (ISRA), VanEck Pharmaceutical ETF (PPH), ARK Israel Innovative Technology ETF (IZRL), Affinity World Leaders Equity ETF (WLDR), iShares MSCI Intl Value Factor ETF (IVLU) and Goldman Sachs ActiveBeta International Equity ETF (GSIE).iShares MSCI EAFE Value ETF (EFV). What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings? Teva Pharmaceutical Industries issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $2.25-$2.55 for the period, compared to the consensus estimate of $2.40. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.06 billion. What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO? 158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO). What is Teva Pharmaceutical Industries' stock symbol? Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA." Who are Teva Pharmaceutical Industries' major shareholders? Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.62%), Migdal Insurance & Financial Holdings Ltd. (2.10%), Harel Insurance Investments & Financial Services Ltd. (2.10%), State Street Corp (1.76%), Clal Insurance Enterprises Holdings Ltd (1.70%) and Exor Capital LLP (1.54%). Insiders that own company stock include David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Teva Pharmaceutical Industries' stock price today? One share of TEVA stock can currently be purchased for approximately $7.38. How much money does Teva Pharmaceutical Industries make? Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $8.27 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. How many employees does Teva Pharmaceutical Industries have? The company employs 36,826 workers across the globe. How can I contact Teva Pharmaceutical Industries? Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050. This page (NYSE:TEVA) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.